Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | TPMT | P51580 | 1/20 | 0.38 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.34 |
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.33 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.33 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3142251 | 0.88 | CES2 (0.50) | MEN1KMT2ADRD2CES2CES1 | |
| SCHEMBL3713101 | 0.81 | CES2 (0.41) | MEN1KMT2ADRD2TAS1R3TAS1R1 | |
| SCHEMBL24726408 | 0.80 | CES2 (0.38) | MEN1KMT2ADRD2CES2CES1 | |
| SCHEMBL1852011 | 0.79 | GSK3B (0.52) | MEN1KMT2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL30512212 | 0.79 | TAS1R3 (0.43) | MEN1KMT2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12780435 | 0.79 | TAS1R3 (0.43) | MEN1KMT2ATAS1R3TAS1R1TAS1R2 | |
| SCHEMBL960252 | 0.74 | CES2 (0.57) | MEN1KMT2ADRD2CES2CES1 | |
| SCHEMBL29649064 | 0.74 | CES2 (0.57) | MEN1KMT2ADRD2CES2CES1 | |
| SCHEMBL5223999 | 0.74 | CES2 (0.46) | TAS1R3TAS1R1TAS1R2CES2CES1 | |
| SCHEMBL572200 | 0.74 | TPMT (0.70) | TAS1R3TAS1R1TAS1R2CES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687529-B2 | Substituted propylamine derivatives and methods of their use | WYETH LLC (US) | 2010-03-30 | — | — | US | disclosed |
| US-7601744-B2 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2009-10-13 | — | — | US | disclosed |
| EP-1934193-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | Wyeth a Corporation of the State of Delaware (US) | 2008-06-25 | — | — | EP | disclosed |
| EP-1934178-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2008-06-25 | — | — | EP | disclosed |
| WO-2007041258-A1 | BENZOTHIADIAZOLYPHENYLALKYLAMINE DERIVATIVES FOR USE IN THE TREATMENT OF CONDITIONS AMELIORATED BY MONOAMINE REUPTAKE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007041257-A2 | SUBSTITUTED PROPYLAMINE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | WYETH (US) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072928-A1 | treatment of conditions ameliorated by monoamine reuptake including vasomotor symptoms, sexual dysfunction, gastrointestinal and genitourinary disorders, chronic fatigue syndrome, fibromylagia syndrome, nervous system disorders; 1'-[3-(methylamino)-1-phenylpropyl]spiro[cyclohexane-1,3'-indol]-2'(1'H)-one | TPH1, HTR1A, HTR5A | MEN1 1129/4885KMT2A 1478/4885DRD2 236/4885 |
| US-20070072918-A1 | Benzothiadiazolylphenylalkylamine derivatives and methods of their use | GLS, SLC6A4, SLC6A3 | MEN1 3154/4885KMT2A 1787/4885DRD2 608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.